MétaCan
Menu
← Back to cohort

Adalimumab Long-term Effectiveness in Adalimumab-Naive Patients With Crohnʼs Disease: Final Data From PYRAMID Registry

2017· article· en· W2911326914 on OpenAlexaff
Edward V. Loftus, Geert D’Haens, Walter Reinisch, Jack Satsangi, Remo Panaccione, Sofie Berg, Gabriela Alperovich, Mareike Bereswill, Jasmina Kalabic, Martha Skup, Joel Petersson, Anne Robinson

Bibliographic record

VenueThe American Journal of Gastroenterology · 2017
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsUniversity of Calgary
Fundersnot available
KeywordsMedicineAdalimumabPhysical therapyInternal medicineDisease

Abstract

fetched live from OpenAlex

Introduction: PYRAMID was an international multi-center non-interventional postmarketing registry assessing long-term safety and effectiveness of adalimumab (ADA) as used in routine clinical practice. Patients (Pts) with and without prior ADA experience were allowed to enroll. The final long-term effectiveness of ADA is reported in adult ADA-naïve pts (those who had not received ADA before registry enrollment) with moderate to severe Crohn's disease (CD) who were treated according to the local product label. Methods: All pts entering the registry were followed for up to 6 years. Effectiveness of ADA was measured using Physician's Global Assessment (PGA; [a composite of Harvey Bradshaw Index and rectal bleeding score]), Short Inflammatory Bowel Disease Questionnaire (SIBDQ), and 4 components of the Work Productivity and Activity Impairment (WPAI) questionnaire, including absenteeism, presenteeism, overall work impairment, and activity impairment. Effectiveness measures, captured in all pts who received at least 1 dose of ADA in the registry and had at least 1 post-enrollment measurement, were summarized descriptively by the number of observations that were not missing at each registry visit; data were reported as observed. Values at enrollment are considered as baseline values. Results: Among 5025 pts evaluated in the registry, 2057 (40.9%) were ADA-naïve. Of these, 1199 pts (58.3%) were female; mean age 37.1 years at enrollment. Mean±SD ADA exposure for the ADA-naïve subgroup during the registry was 1118.5±842.3 days. A total of 1082 pts (52.6%) had prior exposure to at least 1 anti-TNF/biologic; 853 (41.5%) and 831 pts (40.4%) used immunomodulators and corticosteroids, respectively, at enrollment. Mean change from baseline in effectiveness measures for pts with CD is shown in the table. Mean PGA score and SIBDQ as well as WPAI domains improved in ADA-naïve pts from enrollment to 1 year and were sustained for up to 6 years (table). No new safety signals were identified in the registry. Conclusion: At 1 year after entering the international postmarketing registry of ADA use in routine clinical practice, clinically meaningful improvements in disease activity, work productivity, and activity impairment were achieved in ADA-naïve pts with moderately to severely active CD. These improvements were maintained for up to 6 years of the registry among the pts who remained in the study.Table: Table. Change from enrollment (baseline) in effectiveness measure scores in ADA-naïve pts with CD ( N =2057)

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.025

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.005
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.002
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.270
Teacher spread0.256 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2017
Admission routes1
Has abstractyes

Explore more

Same venueThe American Journal of Gastroenterology→Same topicInflammatory Bowel Disease→French-language works237,207→